BV vs IVPR
BrightView Holdings, Inc. and Inspire Veterinary Partners, Inc., side by side — 3 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | BV | IVPR |
|---|---|---|
| Revenue | $2.7B | $16.6M |
| Net income | $56.0M | $-14.3M |
| Gross margin | 23.3% | · |
| Net margin | 2.1% | −86.0% |
| Return on equity | 4.4% | · |
| Diluted EPS | $0.13 | · |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $37.6M | $-10.2M |
| Equity | $1.3B | $1.6M |
| Net debt / equity | 0.55× | 7.34× |
| Current ratio | 1.30× | 0.25× |
| Revenue CAGR 5y | 2.6% | · |
| Profit CAGR 5y | · | · |
BV bills 161.1× the revenue of IVPR, and IVPR closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
3 years side by side
| Fiscal year | BV | IVPR |
|---|---|---|
| FY2024 | $2.8B | $16.6M |
| FY2023 | $2.8B | $16.7M |
| FY2022 | $2.8B | $9.8M |
Bottom line
| Fiscal year | BV | IVPR |
|---|---|---|
| FY2024 | $66.4M | $-14.3M |
| FY2023 | $-7.7M | $-14.8M |
| FY2022 | $14.0M | $-4.9M |
Standard deviation, each side
IVPR's net margin has been more volatile than BV's over the 3 comparable fiscal years — 17.7 percentage points of standard deviation against 1.1.
3 of 9 comparable fiscal years — a year missing data on either side is not counted.
Year by year
BV led in net margin in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 9 comparable fiscal years — a year missing data on either side is not counted.